Eric Verspyck
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Eric Verspyck has a total of 195 co-authors. Here are the top co-authors by number of shared publications:
- L. Marpeau
Service de gynécologie-obstétrique, CHU Charles-Nicolle, 1, rue de Germont, 76000 Rouen, France
20 shared publications - Fabrice Sergent
Clinique gynécologique et obstétricale, CHU Charles-Nicolle, 1, rue de Germont, 76031 Rouen cedex, France
7 shared publications - Stéphane Marret
University Rouen Normandie, INSERM U1245, Team Epigenetics and Pathophysiology of Neurodevelopmental Disorders, 76183 Rouen, France
7 shared publications - Loïc Sentilhes
Department of Obstetrics and Gynecology Bordeaux University Hospital Bordeaux France
6 shared publications Loïc Marpeau
Department of Obstetrics and Gynecology, Rouen University Hospital, Rouen, France
5 shared publicationsA Gravier
3 shared publications
Latest Publications
- 20 March 2026
- Published by Elsevier in Gynécologie Obstétrique Fertilité & Sénologie
- Vol. 54 (10) , 513-516
Comment je fais… l’analyse du chiasma et des voies optiques en prénatal ?
- 20 March 2026
- Published by Elsevier in Gynécologie Obstétrique Fertilité & Sénologie
- Vol. 54 (10) , 513-516
Comment je fais… l’analyse du chiasma et des voies optiques en prénatal ?
- 9 October 2025
- Published by Elsevier in Gynécologie Obstétrique Fertilité & Sénologie
- Vol. 53 (12) , 687-693
Neuroprotection périnatale : apport du sulfate de magnésium dans la prévention des troubles du neurodéveloppement de l’enfant prématuré
- 9 October 2025
- Published by Elsevier in Gynécologie Obstétrique Fertilité & Sénologie
- Vol. 53 (12) , 687-693
Neuroprotection périnatale : apport du sulfate de magnésium dans la prévention des troubles du neurodéveloppement de l’enfant prématuré
- 5 June 2024
- Published by Elsevier in Journal of Gynecology Obstetrics and Human Reproduction
- Vol. 53 (8) , 102805
Comparative analysis of quality scores images between second- and third-trimester ultrasound scan
- 5 June 2024
- Published by Elsevier in Journal of Gynecology Obstetrics and Human Reproduction
- Vol. 53 (8) , 102805
Comparative analysis of quality scores images between second- and third-trimester ultrasound scan
- Open Access
- 17 February 2024
- Published by Elsevier in Gynécologie Obstétrique Fertilité & Sénologie
- Vol. 52 (4) , 221-230
TEMPORARY REMOVAL: Mortalité maternelle par pathologies cardiovasculaires en France 2016–2018
- 17 February 2024
- Published by Elsevier in Gynécologie Obstétrique Fertilité & Sénologie
- Vol. 52 (4) , 221-230
Open AccessTEMPORARY REMOVAL: Mortalité maternelle par pathologies cardiovasculaires en France 2016–2018
- Open Access
- 17 February 2024
- Published by Elsevier in Gynécologie Obstétrique Fertilité & Sénologie
- Vol. 52 (4) , 238-245
Mortalité maternelle par hémorragie obstétricale en France 2016–2018
- 17 February 2024
- Published by Elsevier in Gynécologie Obstétrique Fertilité & Sénologie
- Vol. 52 (4) , 238-245
Open AccessMortalité maternelle par hémorragie obstétricale en France 2016–2018
- 12 January 2024
- Published by Elsevier in Gynécologie Obstétrique Fertilité & Sénologie
- Vol. 52 (2) , 95-101
Évolution du taux d’épisiotomies et des lésions obstétricales du sphincter de l’anus depuis les recommandations de 2018
- 12 January 2024
- Published by Elsevier in Gynécologie Obstétrique Fertilité & Sénologie
- Vol. 52 (2) , 95-101
Évolution du taux d’épisiotomies et des lésions obstétricales du sphincter de l’anus depuis les recommandations de 2018
- 15 September 2023
- Published by Elsevier in American Journal of Obstetrics & Gynecology MFM
- Vol. 5 (11) , 101162
Screening for small for gestational age infants in early vs late third-trimester ultrasonography: a randomized trial
- 15 September 2023
- Published by Elsevier in American Journal of Obstetrics & Gynecology MFM
- Vol. 5 (11) , 101162
Screening for small for gestational age infants in early vs late third-trimester ultrasonography: a randomized trial
- 15 September 2023
- Published by Springer Nature in Pediatric Drugs
- Vol. 26 (1) , 71-81
Low-Dose Remifentanil in Preterm Cesarean Section with General Anesthesia: A Randomized Controlled Trial
Background and Objective The conventional technique of general anesthesia induction during a Cesarean section involves the use of opioids only after cord clamping. We hypothesized that the use of remifentanil before cord clamping might reduce the use of maternal supplemental anesthetic agents and improve the maternal hemodynamics status and neonatal adaptation of the preterm neonate. Methods A phase III, double-blind, randomized, placebo-controlled, hospital-based trial enrolled parturients undergoing a Cesarean section under general anesthesia before 37 weeks of gestation. Block randomization allocated pregnant women to remifentanil or placebo. The primary outcome was the rate of newborns with Apgar scores < 7 at 5 min. Secondary outcomes were maternal hemodynamic parameters, complications of anesthetic induction, use of adjuvant anesthetic agents, neonatal respiratory distress, umbilical cord pH, and lactate levels. Results A total of 52/55 participants were analyzed, comprising 27 women in the remifentanil group and 25 in the placebo group. Nine of 27 (33.3%) neonates had an Apgar score < 7 at 5 min in the remifentanil group versus 11/25 (44.0%) in the placebo group (p = 0.45, odds ratio = 0.66, 95 confidence interval 0.20–2.18). The blood cord gases, cognitive, behavior, sensory, sleeping, and feeding scores at 1 and 2 years of corrected age were not different. For the mothers, hemodynamic parameters, anesthesia duration, and the cumulative treatment dose until cord clamping did not differ between the groups. Conclusions The use of a low dose of remifentanil before cord clamping for a Cesarean section appears to be safe both for the mother and the preterm newborn, but it does not improve maternal or neonatal outcomes. Clinical Trial Registration ClinicalTrials.gov: NCT02029898.
- 15 September 2023
- Published by Springer Nature in Pediatric Drugs
- Vol. 26 (1) , 71-81
Low-Dose Remifentanil in Preterm Cesarean Section with General Anesthesia: A Randomized Controlled Trial
Background and Objective The conventional technique of general anesthesia induction during a Cesarean section involves the use of opioids only after cord clamping. We hypothesized that the use of remifentanil before cord clamping might reduce the use of maternal supplemental anesthetic agents and improve the maternal hemodynamics status and neonatal adaptation of the preterm neonate. Methods A phase III, double-blind, randomized, placebo-controlled, hospital-based trial enrolled parturients undergoing a Cesarean section under general anesthesia before 37 weeks of gestation. Block randomization allocated pregnant women to remifentanil or placebo. The primary outcome was the rate of newborns with Apgar scores < 7 at 5 min. Secondary outcomes were maternal hemodynamic parameters, complications of anesthetic induction, use of adjuvant anesthetic agents, neonatal respiratory distress, umbilical cord pH, and lactate levels. Results A total of 52/55 participants were analyzed, comprising 27 women in the remifentanil group and 25 in the placebo group. Nine of 27 (33.3%) neonates had an Apgar score < 7 at 5 min in the remifentanil group versus 11/25 (44.0%) in the placebo group (p = 0.45, odds ratio = 0.66, 95 confidence interval 0.20–2.18). The blood cord gases, cognitive, behavior, sensory, sleeping, and feeding scores at 1 and 2 years of corrected age were not different. For the mothers, hemodynamic parameters, anesthesia duration, and the cumulative treatment dose until cord clamping did not differ between the groups. Conclusions The use of a low dose of remifentanil before cord clamping for a Cesarean section appears to be safe both for the mother and the preterm newborn, but it does not improve maternal or neonatal outcomes. Clinical Trial Registration ClinicalTrials.gov: NCT02029898.
- Open Access
- 14 February 2023
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 130 (7) , 729-739
Serial plotting of symphysis–fundal height and estimated fetal weight to improve the antenatal detection of infants small for gestational age: A cluster randomised trial
Objective: To assess whether standardised longitudinal reporting of growth monitoring information improves antenatal detection of infants who are small for gestational age (SGA), compared with usual care.Design: Cluster‐randomised controlled trial.Setting: Sixteen French level‐3 units in 2018–2019.Population: Singleton pregnancies.Methods: The intervention consisted of the serial plotting of symphysis–fundal height (SFH) and estimated fetal weight (EFW) measurements on customised growth charts using a software program, compared with standard antenatal care. We estimated relative risks (RR) adjusted for known risk factors for fetal growth restriction (FGR).Main Outcome Measures: The primary outcome was antenatal detection of FGR among SGA births (with birthweights below the tenth centile of French customised curves), defined as the mention of suspected FGR in medical records and either referral ultrasounds for growth monitoring or indicated delivery for FGR. Secondary outcomes were false‐positive rates, mode of delivery, perinatal morbidity and mortality, and number of antenatal visits and ultrasounds.Results: In total, seven intervention clusters (n = 4349) and eight control clusters (n = 4943) were analysed, after the exclusion of one intervention centre for a major deviation in protocol. SGA births represented 613 (14.1%) and 626 (12.7%) of all births, respectively. The rates of antenatal detection of FGR among SGA births were 40.0% in the intervention arm versus 37.1% in the control arm (crude RR 1.08, 95% CI 0.87–1.34; adj RR 1.09, 95% CI 0.88–1.35). No benefits of the intervention were detected in the analyses of secondary outcomes.Conclusions: Serial plotting of SFH and EFW measurements on customised growth charts did not improve the antenatal detection of FGR among SGA births.
- 14 February 2023
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 130 (7) , 729-739
Open AccessSerial plotting of symphysis–fundal height and estimated fetal weight to improve the antenatal detection of infants small for gestational age: A cluster randomised trial
Objective: To assess whether standardised longitudinal reporting of growth monitoring information improves antenatal detection of infants who are small for gestational age (SGA), compared with usual care.Design: Cluster‐randomised controlled trial.Setting: Sixteen French level‐3 units in 2018–2019.Population: Singleton pregnancies.Methods: The intervention consisted of the serial plotting of symphysis–fundal height (SFH) and estimated fetal weight (EFW) measurements on customised growth charts using a software program, compared with standard antenatal care. We estimated relative risks (RR) adjusted for known risk factors for fetal growth restriction (FGR).Main Outcome Measures: The primary outcome was antenatal detection of FGR among SGA births (with birthweights below the tenth centile of French customised curves), defined as the mention of suspected FGR in medical records and either referral ultrasounds for growth monitoring or indicated delivery for FGR. Secondary outcomes were false‐positive rates, mode of delivery, perinatal morbidity and mortality, and number of antenatal visits and ultrasounds.Results: In total, seven intervention clusters (n = 4349) and eight control clusters (n = 4943) were analysed, after the exclusion of one intervention centre for a major deviation in protocol. SGA births represented 613 (14.1%) and 626 (12.7%) of all births, respectively. The rates of antenatal detection of FGR among SGA births were 40.0% in the intervention arm versus 37.1% in the control arm (crude RR 1.08, 95% CI 0.87–1.34; adj RR 1.09, 95% CI 0.88–1.35). No benefits of the intervention were detected in the analyses of secondary outcomes.Conclusions: Serial plotting of SFH and EFW measurements on customised growth charts did not improve the antenatal detection of FGR among SGA births.
- Open Access
- 9 October 2022
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 130 (3) , 257-263
Maternal sudden death: A nationwide retrospective study
Objective: To determine the prevalence of maternal sudden death (MSD) and to compare the characteristics of death between women with explained and unexplained sudden death.Design: A national retrospective study in France.Population: Maternal deaths related to an unexpected sudden cardiac arrest were extracted from the French National Confidential Enquiry into Maternal Deaths database for 2007–2012.Methods: Maternal, pregnancy, sudden death characteristics and maternal investigations were compared between women with explained and unexplained cause of death.Results: A total of 83 maternal sudden deaths and 4 949 890 live births occurred over the period studied, thus accounting for 16% of all maternal deaths (n = 510). Death was explained in 51 (61%) women and unexplained in 32 women (39%). Compared with women with unexplained death, women with explained death were more often found to have in‐hospital cardiac arrest (47% versus 12%, P < 0.01), witnessed cardiac arrest (86% versus 62%, P = 0.03) and in‐hospital death (82% versus 47%, P < 0.01). Postmortem investigations such as autopsy and/or CT scan (65% versus 31%, P < 0.01) were also more often carried out in women with explained death. The proportion of deaths for which the preventability factors could not be assessed was 58% among unexplained MSD and 7% among explained MSD.Conclusion: Maternal sudden death is a rare event but accounts for a high proportion of all maternal deaths. This highlights the importance of providing training in diagnostic and management strategy for care providers. Systematic postmortem investigations are required to help understand causes and improve practices.
- 9 October 2022
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 130 (3) , 257-263
Open AccessMaternal sudden death: A nationwide retrospective study
Objective: To determine the prevalence of maternal sudden death (MSD) and to compare the characteristics of death between women with explained and unexplained sudden death.Design: A national retrospective study in France.Population: Maternal deaths related to an unexpected sudden cardiac arrest were extracted from the French National Confidential Enquiry into Maternal Deaths database for 2007–2012.Methods: Maternal, pregnancy, sudden death characteristics and maternal investigations were compared between women with explained and unexplained cause of death.Results: A total of 83 maternal sudden deaths and 4 949 890 live births occurred over the period studied, thus accounting for 16% of all maternal deaths (n = 510). Death was explained in 51 (61%) women and unexplained in 32 women (39%). Compared with women with unexplained death, women with explained death were more often found to have in‐hospital cardiac arrest (47% versus 12%, P < 0.01), witnessed cardiac arrest (86% versus 62%, P = 0.03) and in‐hospital death (82% versus 47%, P < 0.01). Postmortem investigations such as autopsy and/or CT scan (65% versus 31%, P < 0.01) were also more often carried out in women with explained death. The proportion of deaths for which the preventability factors could not be assessed was 58% among unexplained MSD and 7% among explained MSD.Conclusion: Maternal sudden death is a rare event but accounts for a high proportion of all maternal deaths. This highlights the importance of providing training in diagnostic and management strategy for care providers. Systematic postmortem investigations are required to help understand causes and improve practices.